JPH03184922A - Skin drug for external use - Google Patents

Skin drug for external use

Info

Publication number
JPH03184922A
JPH03184922A JP32468689A JP32468689A JPH03184922A JP H03184922 A JPH03184922 A JP H03184922A JP 32468689 A JP32468689 A JP 32468689A JP 32468689 A JP32468689 A JP 32468689A JP H03184922 A JPH03184922 A JP H03184922A
Authority
JP
Japan
Prior art keywords
skin
capsules
radiation
protective substance
percutaneous absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP32468689A
Other languages
Japanese (ja)
Inventor
Taihei Hamazaki
浜崎 大平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Orbis Holdings Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Priority to JP32468689A priority Critical patent/JPH03184922A/en
Publication of JPH03184922A publication Critical patent/JPH03184922A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To obtain a skin drug for external use, capable of promoting percutaneous absorption and useful for stabilizing a radiation injury protective substance and reducing injuries due to exposure to radiation at a low dose for a long period by using capsules enclosing the radiation injury protective substance and a percutaneous absorption adjuvant in combination. CONSTITUTION:A skin drug for external use obtained by using capsules enclosing a radiation injury protective substance such as a sulfur-containing amino acid (e.g. glutathione or cysteine) or an active oxygen eliminator (e.g. superoxide dismutase or catalase) and a percutaneous absorption adjuvant, preferably glycerol, polyethylene glycol or lecithin in combination. A salt of alginic acid or compression disintegrable soft spherical resin is used as a coating layer for the aforementioned capsules. The capsules are broken with pressure of fingers, etc., to discharge the radiation injury protective substance enclosed therein and the percutaneous absorption adjuvant is mixed therewith. The resultant mixture is then applied to the objective part of a living body.

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は、皮膚外用剤に関し、詳しくは低線量放射線の
長期被曝による障害を低減させるために、不安定な放射
線障害防護物質をカプセルに内包して安定化させ、且つ
、経皮吸収助剤と併用することにより、生体内でその放
射線障害防護効果を増進させた皮膚外用剤である。
Detailed Description of the Invention [Field of Industrial Application] The present invention relates to a topical preparation for skin, and more specifically, the present invention relates to a skin preparation for external use, and more specifically, to reduce damage caused by long-term exposure to low-dose radiation, an unstable radiation protection substance is encapsulated in a capsule. This is an external preparation for skin that has been stabilized by using a transdermal absorption agent, and has enhanced its radiation damage protection effect in vivo by being used in combination with a transdermal absorption aid.

[従来の技術] 最近、オゾン層の破壊、酸性雨、原子力発電所の事故な
どによる地球環境の悪化、あるいは医療用X線照射の影
響が話題になっているが、生体は無意識のうちに長期に
わたって自然放射線、宇宙線や電離放射線などの低線量
放射線の被曝にさらされている。
[Conventional technology] Recently, the deterioration of the global environment due to the destruction of the ozone layer, acid rain, accidents at nuclear power plants, and the effects of medical X-ray irradiation have become a hot topic. exposed to low-dose radiation such as natural radiation, cosmic rays and ionizing radiation.

放射線影響研究所(広島市)の疫学的調査にJ:ると、
ルムという低レベルの放射線の被曝であっても、ガン死
が増加しているとの報告もある。
J: Participated in an epidemiological survey conducted by the Radiation Effects Research Institute (Hiroshima City).
There are also reports that cancer deaths are increasing even with low-level radiation exposure.

この他にも、晩発生障害として、老化や脱毛への影響を
指摘する人もいる。
In addition to this, some people point out the effects on aging and hair loss as late-onset disorders.

そこで、放射線障害を低減させるため、放射線障害防護
物質の研究も行われてきたく例えば、田中敬正、化学と
工業、 39[9]、681(1986) 、 、アイ
ソトープ便覧、210頁1日本アイソトープ協会編、為
永美和子ら、看護学雑誌、 51[6]、580(19
87) 。
Therefore, in order to reduce radiation damage, research has been conducted on substances that protect against radiation damage. , Miwako Tamenaga et al., Nursing Journal, 51 [6], 580 (19
87).

北山滋、化学と生物、 27[5]、297(1989
)、、特開昭54−138130号、特開昭57−97
58号、特開昭62−174021号など参照)。
Shigeru Kitayama, Chemistry and Biology, 27[5], 297 (1989
),, JP-A-54-138130, JP-A-57-97
No. 58, JP-A No. 62-174021, etc.).

[発明が解決しようとする課題] しかしながら、これら放射線障害防護物質は、いずれも
不安定であり、空気中に放置するだけでも分解がおこり
易く、特異臭を放ったり、効果が低減するなど使用性が
悪かった。
[Problems to be solved by the invention] However, all of these radiation hazard protection substances are unstable and easily decompose even when left in the air, giving off a peculiar odor and reducing their effectiveness. was bad.

更に、これら放射線障害防護物質を皮膚に塗布しても経
皮吸収性が少なくその効果もあまり期待できなかった。
Furthermore, even if these radiation damage protective substances were applied to the skin, their percutaneous absorption was low and their effects could not be expected to be much.

本発明者は、公知の放射線障害防護物質を安定化させ、
且つ経皮吸収性が促進した使用性のよい皮膚外用剤を作
ることを課題とした。
The present inventor stabilizes a known radiation protection substance,
The objective was to create an easy-to-use external skin preparation with enhanced transdermal absorption.

[課題を解決するための手段] 本発明は、放射線障害防護物質を内包するカプセルと、
経皮吸収助剤とを併用することを特徴とする皮膚外用剤
であり、好ましい態様としては、放射線障害防護物質が
含硫アミノ酸または/及び活性酸素消去剤であり、カプ
セルの被覆層がアルギン酸塩もしくは圧縮崩壊性軟質球
状樹脂であり、経皮吸収助剤が、グリセリン、ポリエチ
レングリコール、レシチンの一種または二種以上からな
る皮膚外用剤である。
[Means for Solving the Problems] The present invention provides a capsule containing a radiation protection substance;
It is a skin external preparation characterized by being used in combination with a transdermal absorption aid, and in a preferred embodiment, the radiation damage protective substance is a sulfur-containing amino acid or/and an active oxygen scavenger, and the capsule coating layer is an alginate. Alternatively, it is a soft spherical resin that disintegrates under compression, and the transdermal absorption aid is an external preparation for skin comprising one or more of glycerin, polyethylene glycol, and lecithin.

以下、本発明の詳細な説明する。The present invention will be explained in detail below.

本発明で用いる放射線障害防護物質とは、公知のものを
そのま)使用することができる。
As the radiation protection substance used in the present invention, any known substance can be used as is.

例えば、含硫アミノ酸としては、グルタチオン。For example, glutathione is a sulfur-containing amino acid.

、システィン、システアミン及びこれらの誘導体などで
あり、アミン類としては、セロトニンなどであり、活性
酸素消去剤としては、スーパーオキシドジスムターゼ及
びこれらの誘導体(以下、SODと略称する。〉、カタ
ラーゼ、ベルオキシダゼ、メタロチオネインなどであり
、これらを−種または二種以上混合して使用することが
できる。
, cysteine, cysteamine, and their derivatives, etc.; amines include serotonin; active oxygen scavengers include superoxide dismutase and derivatives thereof (hereinafter abbreviated as SOD), catalase, peroxidase, metallothionein, etc., and these species or a mixture of two or more species can be used.

これら放射線障害防護物質のうち、生体内成分であるか
、副作用が少ないかどうかを考慮すると、特に、グルタ
チオン、システィン、SOD、カタラーゼが優れている
Among these substances that protect against radiation damage, glutathione, cysteine, SOD, and catalase are particularly excellent when considering whether they are components in the body and whether they have few side effects.

次に、本発明で用いる被覆層としては、天然高分子でも
合成高分子でもよい。
Next, the coating layer used in the present invention may be a natural polymer or a synthetic polymer.

天然高分子としては、海藻由来のアルギン酸塩が、また
合成高分子としては、メタクリル酸エステル、シアノア
クリル酸類などが使用できる。
As the natural polymer, alginates derived from seaweed can be used, and as the synthetic polymers, methacrylic acid esters, cyanoacrylic acids, etc. can be used.

本発明のカプセルを製造するには、人造イクラの製造方
法を参考にすることができる〈例えば、特公昭61−4
3029号、特開昭58−16649号、特公昭61−
4509号、特開昭61−21070号、特開平01−
91762号、特開平01−123625号など参照〉
。尚、カプセルの被覆層の厚さや強度は、アルギン酸塩
とカルシウムイオンの濃度及び反応時間によって調整す
ることができる。また、カプセルの安定性を向上させる
ためには、内包物の相溶性、流動性、比重、浸透圧を、
逆に使用時の崩壊性についても考慮することが重要であ
る。
To manufacture the capsules of the present invention, the method for manufacturing artificial salmon roe may be referred to (for example, Japanese Patent Publication No. 61-4
No. 3029, JP-A-58-16649, JP-A-61-
No. 4509, JP-A-61-21070, JP-A-01-
91762, JP-A-01-123625, etc.>
. The thickness and strength of the capsule coating layer can be adjusted by adjusting the concentrations of alginate and calcium ions and reaction time. In addition, in order to improve the stability of capsules, it is necessary to improve the compatibility, fluidity, specific gravity, and osmotic pressure of the inclusions.
Conversely, it is important to consider disintegration during use.

更に、本発明のカプセルを製造する方法として、圧縮崩
壊性軟質球状樹脂によるカプセル化法も参考にすること
ができる(例えば、特開昭60−224609号、特開
昭64−43343Qなど参照)。
Furthermore, as a method for producing the capsules of the present invention, encapsulation using a compression-disintegrable soft spherical resin can also be referred to (see, for example, JP-A-60-224609, JP-A-64-43343Q, etc.).

次に、本発明で用いる経皮吸収助剤とは、グリセリン、
ポリエチレングリコールなどの多価アルコール、ヒアル
ロン酸などの角質層の保湿成分、界面活性剤、レシチン
類などであるが、安全性と分散性からグリセリン、ポリ
エチレングリコール、レシチンが優れている。
Next, the transdermal absorption aids used in the present invention include glycerin,
These include polyhydric alcohols such as polyethylene glycol, moisturizing ingredients for the stratum corneum such as hyaluronic acid, surfactants, and lecithins, but glycerin, polyethylene glycol, and lecithin are superior in terms of safety and dispersibility.

次に、本発明品が、放射線障害防護物質を安定化させ、
経皮吸収が促進された皮膚外用剤であることについて述
べる。
Next, the product of the present invention stabilizes the radiation hazard protection substance,
This article describes that it is an external preparation for skin with enhanced transdermal absorption.

(1)安定性テスト (i)放射線障害防護物質(グルタチオン〉の保存安定
性 く実験方法と結果〉 (試料と評価法) グルタチオンを、各種溶媒(精製水、0.5%水酸化ナ
トリウム水、ポリエチレングリコール400〉に分散さ
せたもの及び本発明の実施例1〈皮膚外用剤(1)〉を
各々密封し、40’Cに1ケ月間放置後に開封して、変
臭の程度を官能評価した。
(1) Stability test (i) Storage stability of radiation protection substance (glutathione) Experimental method and results The dispersion in polyethylene glycol 400 and Example 1 of the present invention (external skin preparation (1)) were each sealed and left at 40'C for one month, then opened and the degree of odor was sensory evaluated. .

(結 果〉 グルタチオンを各種溶媒に分散させたものはいずれもイ
オウ臭がしたが、本発明品を手のひらにとり指の圧力で
カプセルを割ったものは、はとんどイオウ臭がしない。
(Results) All of the products in which glutathione was dispersed in various solvents had a sulfur odor, but when the product of the present invention was placed in the palm of the hand and the capsule was broken with finger pressure, there was almost no sulfur odor.

つまり、本発明品では、グルタチオンが安定に保たれて
いることがわかる。
In other words, it can be seen that glutathione is stably maintained in the product of the present invention.

(ii)  カプセルの保存安定性 〈実験方法と結果〉 (試料と評価法) 本発明の実施例1のカプセル体3個を秤量ビンにとり、
1/2量の下記分散媒を加えてカプセル体を分散させ、
密封して、室温にて2週間放置接状態変化を肉眼で観察
した。
(ii) Storage stability of capsules <Experimental method and results> (Sample and evaluation method) Three capsule bodies of Example 1 of the present invention were placed in a weighing bottle,
Add 1/2 amount of the following dispersion medium to disperse the capsules,
The container was sealed and left at room temperature for 2 weeks, and changes in the state of contact were observed with the naked eye.

(結 果) 上表より、明らかなように、カプセル体の保存にはグリ
セリンやポリエチレングリコールが優れていることがわ
かる。
(Results) As is clear from the above table, glycerin and polyethylene glycol are superior in preserving capsule bodies.

(2)経皮吸収性テスト 〈実験方法と結果〉 (a)試料 試料1:実施例1のグルタチオンを標識グルタチオン(
30−ゲルタデオン〉とし、 皮膚外用剤(1)を手のひらにとり、指の圧力でカプセ
ル体を割り、グリセリ ンとよく混合したもの。
(2) Transdermal absorption test <Experimental method and results> (a) Sample sample 1: Glutathione from Example 1 was converted into labeled glutathione (
30-Geltadeone>, take the skin external preparation (1) in the palm of your hand, break the capsule body with finger pressure, and mix well with glycerin.

試料2:実施例1のグルタチオンを標識−グルタチオン
(30−グルタチオン〉とし、カプセル体のみ(グリセ
リンを含まな い〉を指でつぶしたもの。
Sample 2: The glutathione of Example 1 was labeled as glutathione (30-glutathione), and the capsule alone (not containing glycerin) was crushed with fingers.

(b)実験方法 実験動物として、ハートレイ系モルモット5羽を選ぶ。(b) Experimental method Five Hartley guinea pigs were selected as experimental animals.

投与直前に、背部正中線の左右を電気バリカンと電気カ
ミソリで除毛部位を作り、試料1を左の部位に、試料2
を右の部位に塗布する。
Immediately before administration, hair removal sites were created on the left and right sides of the dorsal midline using electric clippers and an electric razor, and sample 1 was placed on the left site and sample 2 was placed on the left side.
Apply to the right area.

24時間後貼り替え、48時間後にモルモットをサクリ
ファイスし、各投与部位の皮膚組織を採取し、直ちに、
ドライアイス中に凍結する。
Reapply after 24 hours, sacrifice the guinea pigs after 48 hours, collect skin tissue from each administration site, and immediately
Freeze in dry ice.

よりロトームで、50μmの凍結切片を作る。Frozen sections of 50 μm are made using a rotome.

切片をスライドグラス上に移し、暗室中にてオドラジオ
グラフィック・ストリッピング・フィルムを被せる。
Transfer the sections onto glass slides and cover with odoradiographic stripping film in the dark.

フィルムを現像・定着後、ハリスのヘマトキシリンにて
核染色を行う。
After developing and fixing the film, perform nuclear staining with Harris hematoxylin.

銀粒子の分布状態を肉眼で観察する。Observe the distribution state of silver particles with the naked eye.

(C)結果 試料1の場合には、毛のうの毛幹にそって銀粒子が分布
しているが、試料2の場合には、はとんど投与部位にと
どまっている。
(C) Results In the case of sample 1, the silver particles are distributed along the hair shaft of the hair follicle, but in the case of sample 2, they mostly remain at the administration site.

すなわち、グルタチオンとグリセリンとを併用すること
により、放銅線障害防護物質のグルタチオンが経皮吸収
助剤のグリセリンによって経皮吸収され易くなったこと
がわかる。
That is, it can be seen that by using glutathione and glycerin together, glutathione, which is a substance that protects against damage to the copper wire, is easily absorbed through the skin by glycerin, which is a transdermal absorption aid.

[実施例] 以下、実施例を挙げて、本発明をさらに具体的に説明す
るが、本発明がこれらに限定されるものではない。
[Examples] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited thereto.

尚、配合量は重量部である。Incidentally, the blending amount is in parts by weight.

実施例1.皮膚外用剤(1) ■ カプセル体の調製  0 内包される(八)成分を室温にて随伴し、均一に分散さ
せ、ゾル状物を作る。
Example 1. External skin preparation (1) ■ Preparation of capsule 0 Component (8) to be encapsulated is entrained at room temperature and uniformly dispersed to form a sol.

このゾル状物を、内径5Mの管状ノズルより、(B)溶
液に滴下させる。更に、この粒体をとり出し、(C)溶
液にうつし、被覆層に強度をもたせた球状のカプセル体
が得られる。水で軽く洗う。
This sol-like material is dropped into the solution (B) from a tubular nozzle with an inner diameter of 5M. Furthermore, the granules are taken out and placed in solution (C) to obtain spherical capsules with a strong coating layer. Wash lightly with water.

■ 皮膚外用剤(1)の調製 容器にこのカプセル体をとり、同重量のグリセリンを加
えて分散させ、製品とする。
(2) Preparation of external skin preparation (1) Place the capsule in a container and add the same weight of glycerin to disperse it to obtain a product.

(以下余白) 実施例2゜ 皮膚外用剤(2) ■ カプセル体の調製 〔 ) 内包物 ホモミキサーに(A) を取り、 室温にて随伴し、 均一に溶解する。これに随伴しながら、均一に分散した
(8)を加えて乳化し、高粘性の乳化物を得る。
(Space below) Example 2゜External skin preparation (2) ∎ Preparation of capsule [ ) Take (A) into an inclusion homomixer, mix at room temperature, and dissolve uniformly. Along with this, uniformly dispersed (8) is added and emulsified to obtain a highly viscous emulsion.

(ii)カプセル体の調製 この乳化物を、内径5Mの管状ノズルより1%アルギン
酸ナトリウム水溶液中に滴下させて粒体を得る。
(ii) Preparation of capsules This emulsion is dropped into a 1% aqueous sodium alginate solution through a tubular nozzle with an inner diameter of 5M to obtain granules.

更に、この粒体を2%塩化カルシウム水溶液に移し、被
覆層に強度をもたせたカプセル体を得る。
Furthermore, this granule is transferred to a 2% calcium chloride aqueous solution to obtain a capsule body with a strong coating layer.

水で軽く洗う。Wash lightly with water.

■ 皮膚外用剤(2)の調製 容器にカプセル体をとり、これと172重量のポリエチ
レングリコール400を加え、軽く振ってカプセル体を
分散状態とし、製品とする。
(2) Preparation of external skin preparation (2) Place the capsules in a container, add 172 weight of polyethylene glycol 400, and shake lightly to disperse the capsules to obtain a product.

■ 使用法 カプセル1個を手のひらにとり、指の圧力でカプセルを
割り、安定に内包された放射線障害防護物質のSODを
放出させ、経皮吸収助剤のポリエチレングリコール40
0と混和させ、必要なら被覆層を除いて、目的の生体部
位に塗布する。
■ How to use: Place one capsule in the palm of your hand and break the capsule with finger pressure to release the stably contained SOD, a radiation protection substance, and polyethylene glycol 40, a transdermal absorption aid.
0 and apply to the desired biological site, removing the coating layer if necessary.

3 実施例3.皮膚外用剤(3) ■ 圧縮崩壊性軟質球状樹脂カプセル体の調製ホモミキ
サーに(イ〉をとり、室温にて8.0007Umで高速
回転させ、(ロ)をゆっくり加え、油中水型エスルショ
ンを作る。ホモミキサーの回転数を1,000γpmに
おとし、(ハ)をゆっくり加え、水中曲中水型多重エマ
ルシ」ンを作る。
3 Example 3. Skin external preparation (3) ■ Preparation of compression-disintegrable soft spherical resin capsules Place (A) in a homomixer, rotate at high speed at 8.0007 Um at room temperature, slowly add (B), and add water-in-oil esulsion. Set the rotation speed of the homomixer to 1,000 γpm and slowly add (c) to make a water-in-water type multiple emulsion.

アスピレータ−減圧下でi〜ルエンを留去する。Aspirator - Distill the toluene under reduced pressure.

4 濾過して、システィンを内包するメタクリル酸メチル/
酢酸ビニル共重合体被膜のカプセル体を得る。
4 Filtered methyl methacrylate containing cysteine/
A capsule body coated with vinyl acetate copolymer is obtained.

■ 皮膚外用剤(3)の調製 ヘンシェルミキサーに(A)をとり、低速回転にて5分
間混合した後、粉砕機で粉砕混合づ−る。次いで、この
粉砕混合物をヘンシェルミキサーに移し、常温にて高速
回転しながら(8)をゆっくり加5 える。低速回転にして(C)を加え、2分間混合陛拌す
る。これをブロワ−シフターを通し、容器につめてパウ
ダー状の製品とする。
(2) Preparation of external skin preparation (3) Place (A) in a Henschel mixer, mix at low speed for 5 minutes, and then grind and mix in a grinder. Next, transfer this pulverized mixture to a Henschel mixer, and slowly add (8) while rotating at high speed at room temperature. Rotate at low speed, add (C), and mix for 2 minutes. This is passed through a blower sifter and packed into a container to form a powdered product.

■ 使用法 化粧動作中に、指などの圧力により、カプセルの樹脂被
覆層を破壊し、安定に内包された放射線障害防護物質の
システィンを放出さぜ、経皮吸収助剤のグリセリンと混
合し、生体部位に塗布する。
■ How to use During makeup operation, the resin coating layer of the capsule is destroyed by pressure from fingers, etc., and the stably contained cysteine, a substance that protects against radiation damage, is released, and mixed with glycerin, which is a transdermal absorption aid, Apply to body parts.

[発明の効果] 本発明品は、放射線障害防護物質を安定化させ、且つ、
経皮吸収を促進させた皮膚外用剤である。
[Effect of the invention] The product of the present invention stabilizes the radiation damage protection substance, and
This is an external preparation for skin that promotes transdermal absorption.

Claims (1)

【特許請求の範囲】 1)放射線障害防護物質を内包するカプセルと、経皮吸
収助剤とを、併用することを特徴とする皮膚外用剤。 2)放射線障害防護物質が、含硫アミノ酸または/及び
活性酸素消去剤からなる請求項1)記載の皮膚外用剤。 3)含硫アミノ酸が、グルタチオンやシステインで、活
性酸素消去剤が、スーパーオキシドジスムターゼまたは
その誘導体やカタラーゼであり、これらの一種または二
種以上からなる請求項1)または2)記載の皮膚外用剤
。 4)カプセルの被覆層が、アルギン酸塩もしくは、圧縮
崩壊性軟質球状樹脂からなる請求項1)記載の皮膚外用
剤。 5)経皮吸収助剤が、グリセリン、ポリエチレングリコ
ール、レシチンの一種または二種以上からなる請求項1
)記載の皮膚外用剤。
[Scope of Claims] 1) A skin preparation for external use, characterized in that a capsule containing a radiation protection substance and a transdermal absorption aid are used together. 2) The skin external preparation according to claim 1), wherein the radiation damage protective substance comprises a sulfur-containing amino acid or/and an active oxygen scavenger. 3) The skin external preparation according to claim 1) or 2), wherein the sulfur-containing amino acid is glutathione or cysteine, and the active oxygen scavenger is superoxide dismutase or a derivative thereof, or catalase, and comprises one or more of these. . 4) The skin external preparation according to claim 1), wherein the capsule coating layer is made of alginate or a compressible soft spherical resin. 5) Claim 1 in which the transdermal absorption aid comprises one or more of glycerin, polyethylene glycol, and lecithin.
) External skin preparations listed in ).
JP32468689A 1989-12-14 1989-12-14 Skin drug for external use Pending JPH03184922A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP32468689A JPH03184922A (en) 1989-12-14 1989-12-14 Skin drug for external use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32468689A JPH03184922A (en) 1989-12-14 1989-12-14 Skin drug for external use

Publications (1)

Publication Number Publication Date
JPH03184922A true JPH03184922A (en) 1991-08-12

Family

ID=18168592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP32468689A Pending JPH03184922A (en) 1989-12-14 1989-12-14 Skin drug for external use

Country Status (1)

Country Link
JP (1) JPH03184922A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296500A (en) * 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
EP0623342A1 (en) * 1993-05-07 1994-11-09 L'oreal Use of an alkyl ester of glutathione in a cosmetic or dermatological composition for the topical treatment of skin ageing
US5451405A (en) * 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
EP1004289A3 (en) * 1998-11-27 2000-09-20 Peter T. Pugliese Cosmetic and skin protective compositions comprising catalase
JP2002193790A (en) * 2000-12-27 2002-07-10 Lion Corp Oil-in-water type emulsion containing scarcely water- soluble drug and method of producing the same
JP2015510503A (en) * 2012-11-22 2015-04-09 オリジナル バイオメディカルズ カンパニー,リミテット Pharmaceutical composition for reducing damage caused by free radicals
JP2017530159A (en) * 2014-10-02 2017-10-12 サイトソーベンツ・コーポレーション Use of gastrointestinal administered porous gastrointestinal adsorbent polymer for the prevention or treatment of radiation-induced mucositis, esophagitis, enterocolitis, colitis and gastrointestinal acute radiation syndrome

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296500A (en) * 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
EP0623342A1 (en) * 1993-05-07 1994-11-09 L'oreal Use of an alkyl ester of glutathione in a cosmetic or dermatological composition for the topical treatment of skin ageing
FR2704754A1 (en) * 1993-05-07 1994-11-10 Oreal Use of a glutathione alkyl ester in a cosmetic or dermatological composition for the topical treatment of cutaneous aging.
US5451405A (en) * 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
EP1004289A3 (en) * 1998-11-27 2000-09-20 Peter T. Pugliese Cosmetic and skin protective compositions comprising catalase
JP2002193790A (en) * 2000-12-27 2002-07-10 Lion Corp Oil-in-water type emulsion containing scarcely water- soluble drug and method of producing the same
JP2015510503A (en) * 2012-11-22 2015-04-09 オリジナル バイオメディカルズ カンパニー,リミテット Pharmaceutical composition for reducing damage caused by free radicals
JP2017530159A (en) * 2014-10-02 2017-10-12 サイトソーベンツ・コーポレーション Use of gastrointestinal administered porous gastrointestinal adsorbent polymer for the prevention or treatment of radiation-induced mucositis, esophagitis, enterocolitis, colitis and gastrointestinal acute radiation syndrome
JP2020172528A (en) * 2014-10-02 2020-10-22 サイトソーベンツ・コーポレーション Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation-induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome

Similar Documents

Publication Publication Date Title
JP3972372B2 (en) Cosmetic granular gel carrier for active agents applied topically
ES2200008T3 (en) FOAMABLE FORMULATION AND FOAM.
ES2331953T3 (en) COSMETIC AND THERAPEUTIC USE OF VISCOSE COMPOSITIONS CONTAINING CARBON DIOXIDE.
WO2012063947A1 (en) Gel sheet comprising lipidic peptide type gelling agent and polymeric compound
ES2400069T3 (en) Topical glycopyrronium product
JP2011102317A (en) Gel bead for cosmetic
JPH03135913A (en) Cosmetic or pharmaceutical composition containing micro-spheres of polymer or fatty substance having at least one activated product filled therein
WO2007114904A2 (en) Cosmetic and therapeutic stick products comprising microparticles
JPH03184922A (en) Skin drug for external use
JPH09124469A (en) Adhesive tape for cosmetic or dermatological medicine
JP3984664B2 (en) Wound dressing
EP3946258A1 (en) Fluorouracil-containing formulations
JP2004187970A (en) Lotion tissue paper
JP2010006738A (en) Foamable aerosol composition
BR112014013216B1 (en) anhydrous antiperspirant composition, perspiration reduction method and method of manufacturing an anhydrous antiperspirant composition
US20030199576A1 (en) Stabilized pure vitamin C in powder-to-liquid form using multi-encapsulation method
JP2015034153A (en) Kit for external preparations for skin
KR20200141214A (en) Hydrogel composition, preparing method for hydrogel composition and cosmetic composition including the same
JP3124163B2 (en) Artificial granules
KR20000061633A (en) A cosmetic having hydrogel matrix adsheive sheet type
KR0163834B1 (en) Cosmetic compositions of scrub agents containing spheric collagen particle
JP3031463B2 (en) Bath composition
JP2007529406A (en) Enhanced electrostatic charge nasal products
JPS63295504A (en) Cosmetic
WO2006071584A2 (en) Release particle composition, process for making same, and composition having such particles